ZIGNEGO, ANNA LINDA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 37.245
EU - Europa 21.363
AS - Asia 13.532
SA - Sud America 1.737
AF - Africa 454
OC - Oceania 322
Continente sconosciuto - Info sul continente non disponibili 238
Totale 74.891
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 36.631
RU - Federazione Russa 7.128
IT - Italia 4.156
SG - Singapore 3.918
PL - Polonia 3.089
CN - Cina 2.574
HK - Hong Kong 2.371
IE - Irlanda 1.852
VN - Vietnam 1.520
SE - Svezia 1.454
BR - Brasile 1.378
KR - Corea 1.213
FI - Finlandia 851
UA - Ucraina 730
DE - Germania 713
FR - Francia 623
IN - India 465
GB - Regno Unito 392
TR - Turchia 383
CA - Canada 373
AU - Australia 318
JP - Giappone 298
CI - Costa d'Avorio 170
ID - Indonesia 131
BD - Bangladesh 127
AR - Argentina 117
IQ - Iraq 91
MX - Messico 82
NL - Olanda 72
JO - Giordania 70
CO - Colombia 69
ES - Italia 68
NG - Nigeria 67
EC - Ecuador 56
ZA - Sudafrica 53
BE - Belgio 49
VE - Venezuela 43
PK - Pakistan 40
PH - Filippine 39
AE - Emirati Arabi Uniti 38
SA - Arabia Saudita 38
MA - Marocco 34
CH - Svizzera 33
UZ - Uzbekistan 27
CR - Costa Rica 26
JM - Giamaica 25
MY - Malesia 25
EG - Egitto 24
SC - Seychelles 23
KE - Kenya 22
CZ - Repubblica Ceca 20
PY - Paraguay 20
CL - Cile 19
AZ - Azerbaigian 18
HN - Honduras 18
TH - Thailandia 17
DZ - Algeria 16
TT - Trinidad e Tobago 16
LT - Lituania 15
IL - Israele 14
PE - Perù 13
RO - Romania 13
TW - Taiwan 13
UY - Uruguay 13
TN - Tunisia 12
AT - Austria 11
BG - Bulgaria 11
DO - Repubblica Dominicana 11
PR - Porto Rico 11
AL - Albania 10
EE - Estonia 10
NP - Nepal 10
SY - Repubblica araba siriana 10
KG - Kirghizistan 9
KZ - Kazakistan 9
PT - Portogallo 9
DK - Danimarca 8
EU - Europa 8
GT - Guatemala 8
PA - Panama 8
PS - Palestinian Territory 8
AM - Armenia 7
BB - Barbados 7
BO - Bolivia 7
ET - Etiopia 7
BH - Bahrain 6
HU - Ungheria 6
SN - Senegal 6
SV - El Salvador 6
BY - Bielorussia 5
IR - Iran 5
LB - Libano 5
LV - Lettonia 5
OM - Oman 5
RS - Serbia 5
GE - Georgia 4
GR - Grecia 4
KH - Cambogia 4
MM - Myanmar 4
NO - Norvegia 4
Totale 74.579
Salva come PNG Salva come JPEG
Città #
Santa Clara 6.429
Ashburn 3.386
Warsaw 3.072
Singapore 2.696
Fairfield 2.633
San Jose 2.097
Hong Kong 1.893
Dublin 1.850
Chandler 1.765
Seoul 1.179
Woodbridge 1.164
Seattle 1.096
Cambridge 1.092
Jacksonville 1.025
Wilmington 961
Houston 938
Milan 872
Council Bluffs 704
Beijing 671
The Dalles 614
Princeton 567
Buffalo 527
Los Angeles 509
Altamura 481
Ann Arbor 463
Ho Chi Minh City 458
Lauterbourg 456
Lawrence 437
Boston 387
Rome 377
Boardman 338
Hefei 333
Hanoi 325
Mumbai 322
Helsinki 307
Florence 306
Melbourne 305
Tokyo 285
Medford 272
Izmir 260
New York 258
Moscow 218
Dallas 205
Abidjan 170
San Diego 152
São Paulo 150
Norwalk 145
Munich 134
Shanghai 134
Dong Ket 118
Toronto 118
Phoenix 117
Falls Church 115
Naples 108
Chicago 104
Sunnyvale 95
Jakarta 84
Turin 82
Redondo Beach 81
Bremen 80
Frankfurt am Main 76
Figino 75
Bologna 74
Clifton 71
Hillsboro 68
Abuja 65
Da Nang 65
Paris 59
London 57
Andover 55
Dearborn 55
Montreal 55
Turku 54
Brooklyn 53
Washington 53
Verona 51
Palermo 50
Columbus 48
Haiphong 48
Atlanta 46
Brussels 46
Kent 45
Guangzhou 42
Istanbul 42
Orem 42
San Francisco 40
Bari 39
Philadelphia 38
Genoa 37
Miano 37
Charlotte 34
Venice 33
Denver 32
Frankfurt Am Main 32
Salerno 32
Baghdad 31
Redmond 31
Rio de Janeiro 31
Brescia 30
West Jordan 30
Totale 48.422
Salva come PNG Salva come JPEG
Nome #
Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients 1.211
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 389
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis 388
Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection 369
Hepatitis C Virus infection in the immunocompromised host: a complex scenario with variable clinical impact 340
Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study 328
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 325
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 310
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. 309
Strategie terapeutiche nella crioglobulinemia mista: recenti acquisizioni 298
Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome 293
HCV and lymphoproliferation 290
Identification of new autoantigens by protein array indicates a role for IL4 neutralization in Autoimmune Hepatitis 279
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 279
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 279
Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition 278
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 272
Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. 270
HCV Patients Psychopathology and Tryptophan Metabolism: Analysis of the Effects of Pegylated Interferon plus Ribavirin Treatment 269
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 269
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 267
Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. 267
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 266
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 265
Mixed cryoglobulinemia, lymphomas and HCV 252
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 249
Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases 249
The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy 248
HCV-related liver and lymphoproliferative diseases: Association with polymorphisms of IL28B and TLR2 247
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 244
Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study 243
Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning 242
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 242
International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement 240
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 239
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 238
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 236
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 233
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C 232
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 232
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 231
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort 230
B-cells and mixed cryoglobulinemia 227
"Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease 227
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 226
AISF position paper on HCV in immunocompromised patients 224
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3 224
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1 224
Clinical significance of polymorphisms in immune response genes in hepatitis C-related hepatocellular carcinoma 223
Current and future challenges in HCV: insights from an Italian experts panel 223
Association Between Persistent Lymphatic Infection By Hepatitis C Virus After Antiviral Treatment And Mixed Cryoglobulinemia 221
Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN) 221
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 219
Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC 217
Host genetic determinants in HCV-related mixed cryoglobulinemia 216
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. 216
IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection 215
Treatment of HCV-related mixed cryoglobulinemia 210
Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany 209
A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders 209
Hepatitis C virus in mixed cryoglobulinemia and B cell lymphoma 207
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 207
Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study 207
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 204
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 204
Host genetic determinants in HCV-related mixed cryoglobulinemia 204
Real life experiences in HCV management in 2018 203
From current status to optimization of HCV treatment: Recommendations from an expert panel 203
Analysis of HCV persistence in patients with sustained virological response 199
Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study 199
Hepatocellular carcinoma in mixed cryoglobulinemia patients 198
Combined presence of HCVRNA sequences and t(14;18) (q32;q21) translocation in PBMC from patients with chronic HCV infection 198
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 198
Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non- Hodgkin's lymphoma, and cancer 198
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 197
Chronic hepatitis C and B-cell non-Hodgkin's lymphoma 196
Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment 196
CD81 Modulation by Immobilized Monoclonal Antibodies is Able to Promote B-cell proliferation and C-MYC expression 196
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 192
MR-diffusion imaging in assessing chronic liver diseases: does a clinical role exist? 192
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 192
COMBINED PRESENCE OF HCVRNA SEQUENCES AND T(14;18) (q32;q21) TRANSLOCATION IN PBMC FROM PATIENTS WITH CHRONIC HCV INFECTION. 191
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. 191
Infection of peripheral mononuclear blood cells by hepatitis C virus 190
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. 188
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 188
Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia 188
Different metabolic fingerprints between HCV and HBV patients: a possible interference of the two major hepatitis viruses in basal metabolism pathways. 187
Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab 187
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease 186
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 186
Interferon and thymosin combination therapy in naive patients with chronic hepatitis C. Preliminary results 185
Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients 184
CD81 modulation by immobilized monoclonal antibodies is able to promote B-cell proliferation and c-myc expression 183
Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe 182
Involvement of PI3K in HCV-related lymphoproliferative disorders 181
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 180
Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda 180
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 180
HCV INFECTION OF PERIPHERAL AND LIVER MONONUCLEAR-CELLS - PATHOGENIC IMPLICATIONS 179
Totale 24.094
Salva come PNG Salva come JPEG
Categoria #
all - tutte 208.835
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 208.835
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.689 0 0 0 154 112 129 109 212 120 98 543 1.212
2022/20237.696 875 1.073 303 535 729 1.661 964 385 770 49 239 113
2023/20242.265 142 390 574 119 143 269 35 368 36 70 61 58
2024/202518.782 711 2.158 1.388 2.815 5.866 1.983 197 1.035 1.191 406 560 472
2025/202620.934 2.175 2.832 1.356 1.199 1.975 849 2.714 1.120 1.929 1.289 524 2.972
2026/20274.873 540 975 2.197 1.161 0 0 0 0 0 0 0 0
Totale 74.891